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Evolutionary inactivation of a
sialidase in group B Streptococcus
Masaya Yamaguchi1,2, Yujiro Hirose1,3, Masanobu Nakata1, Satoshi Uchiyama2,
Yuka Yamaguchi2, Kana Goto1, Tomoko Sumitomo1, Amanda L. Lewis4, Shigetada Kawabata1
& Victor Nizet2,5,6
Group B Streptococcus (GBS) is a leading cause of bacterial sepsis and meningitis in newborns.
GBS possesses a protein with homology to the pneumococcal virulence factor, NanA, which
has neuraminidase (sialidase) activity and promotes blood-brain barrier penetration. However,
phylogenetic sequence and enzymatic analyses indicate the GBS NanA ortholog has lost sialidase
function – and for this distinction we designate the gene and encoded protein nonA/NonA. Here
we analyze NonA function in GBS pathogenesis, and through heterologous expression of active
pneumococcal NanA in GBS, potential costs of maintaining sialidase function. GBS wild-type and
ΔnonA strains lack sialidase activity, but forced expression of pneumococcal NanA in GBS induced
degradation of the terminal sialic acid on its exopolysaccharide capsule. Deletion of nonA did not
change GBS-whole blood survival or brain microvascular cell invasion. However, forced expression of
pneumococcal NanA in GBS removed terminal sialic acid residues from the bacterial capsule, restricting
bacterial proliferation in human blood and in vivo upon mouse infection. GBS expressing pneumococcal
NanA had increased invasion of human brain microvascular endothelial cells. Thus, we hypothesize
that nonA lost enzyme activity allowing the preservation of an effective survival factor, the sialylated
exopolysaccharide capsule.
Streptococcus agalactiae (Group B Streptococcus, GBS) is a Gram-positive bacterial pathogen that is a leading
cause of sepsis, pneumonia, and meningitis during neonatal period and up to the first 90 days of life1,2. Each of the
10 different GBS capsular polysaccharide types1, though possessing different repeating subunits, share a terminal
α-2-3-linked sialic acid (N-acetylneuraminic acid, Neu5Ac motif), which is identical to a sugar epitope capping many surface glycans on all mammalian cells3. Humans in particular express just the terminal α-2-3-linked
Neu5Ac since they have lost the gene required to synthesize the alternative sialic acid, N-glycolylneuraminic
acid (Neu5Gc) present in other mammals including primates3. The GBS sialylated capsule mimics a common
presentation of Neu5Ac in the α-2-3-linkage, which contributes to evasion of the host immune system and promoting bacterial survival in vivo4. GBS capsular sialylation interferes with the host complement system to block
C3b deposition and limit C5a deposition5,6, and inhibits neutrophil activation through interaction with inhibitory
sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9)7. The in vivo significance of these findings was corroborated in mice with and without Siglec-E, the closest homolog of human Siglec-9, which interacts with GBS in
a sialic acid-dependent manner, triggering protein tyrosine phosphatase, SHP-1, recruitment to its intracellular
domain and suppressing myeloid cell inflammatory responses8.
Streptococcus pneumoniae (pneumococcus) is a related Gram-positive pathogen and a major cause of pneumonia, sepsis, and meningitis9,10. Most severe S. pneumoniae diseases occur in children younger than 2 years
and adults older than 65 years. The polysaccharide capsule of S. pneumoniae confers the antigenicity utilized
to classify S. pneumoniae into at least 97 serotypes11. In contrast to GBS, no S. pneumoniae strains express sialic
acid in its capsular polysaccharide. Instead, the bacterium expresses three sialic acid-cleaving enzymes or sialidases, NanA, NanB, and NanC11,12. The nanA and nanB genes are located in the same operon and detected in
almost all clinical isolates, whereas the nanC gene is present in approximately half (51%) of isolates12. While the
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molecular functions of NanB and NanC in the pathogenesis are unclear, NanA has been identified as a multifunctional protein contributing to pneumococcal virulence13,14. NanA is a cell-wall-anchored protein and works as an
invasin into human brain microvascular endothelial cells (hBMEC) through its LamG superfamily domain14–16.
An isogenic S. pneumoniae ΔnanA mutant strain showed >90% reduction in adhesion and invasion efficiency
compared to its parent strain; complementation of NanA expression on a plasmid vector restored the adherence/
invasion phenotype. Furthermore, heterologous expression of NanA in Lactococcus lactis conferred an adhesion
and invasion frequency ~10-fold greater than empty-vector-transformed control14. The NanA LamG domain
induces inflammatory cytokine production from the brain endothelial cells, and the resulting cell activation promotes pneumococcal internalization16. In addition, desialylation of leukocyte cell surfaces by NanA resulted in
MAP kinase phosphorylation and NF-κB activation through unmasking of Siglec-517.
Here, we identify through homology searching a putative ortholog of pneumococcal NanA that is present in
GBS strains. The biological consequences for GBS of possessing a potential sialidase enzyme, while simultaneously expressing a sialylated capsule as an essential virulence determinant, were initially unclear. Our bioinformatics analysis suggested that, unlike pneumococcal NanA, the GBS orthologue has lost the LamG domain and
cell wall-anchoring motif, and that there was a nonsense mutation in this gene in some GBS strains. Codon-based
selection analysis indicated that pneumococcal nanA was under stronger negative selection than nonA. We find
that the GBS strains do not possess neuraminidase activity, and for this distinction we designate the gene and
encoded protein nonA/NonA. In contrast to earlier published findings with pneumococcal NanA mutants13,14,16,
targeted deletion of the nonA gene in GBS did not alter resistance to human whole blood killing, brain microvascular endothelial cell invasion, or animal virulence. However, forced expression of active pneumococcal NanA in
the GBS ΔnonA mutant removed terminal sialic acid from the GBS polysaccharide capsule, reducing GBS survival in whole blood, while promoting GBS invasion of brain microvascular endothelial cells. Taken together, our
results strongly suggest that the loss of function as a sialidase in GBS NonA in contemporary GBS strains allowed
the organism to preserve the selective advantage of sialylated capsule.

Results

Evolutionary analysis of a GBS nanA ortholog.

We performed a bioinformatics analysis on the nonA
gene, an ortholog of pneumococcal nanA (SAK_RS09520 or SAK_1891), annotated in the published genome
of GBS strain A909. Amino acid sequence alignment analysis showed that SAK_RS09520 contains a sialidase
domain but lacks the conserved lectin like-domain LamG and cell wall anchoring motifs present in pneumococcal NanA (Fig. 1A). GBS NonA shared 58% amino acid sequence identity with pneumococcal NanA across the
sialidase domain, with lesser degrees of sequence identity with pneumococcal NanB and NanC (27–28% amino
acid sequence identities) (Supplementary Table 1). Next, tBLASTn analysis revealed that a subset of species in
the genus Streptococcus contains nanA orthologs and a phylogenetic analysis was performed using orthologous
bacterial nanA sequences. Both Bayesian- and maximum likelihood phylogenetic analyses of these orthologs
revealed similar patterns of genetic classification with high posterior probabilities or bootstrap values (Fig. 1B,
Supplementary Fig. 1 and Supplementary Table 2). The sialidase genes of Gram-positive and rod-shaped bacteria, Erysipelothrix rhusiopathiae, Clostridium perfringens, and Virgibacillus sp., were used to root, since with
the exception of homologous genes from other streptococci, these genes exhibited the highest similarity with
pneumococcal nanA. E. rhusiopathiae and C. perfringens are known to produce active sialidases18–20. Both trees
indicate that the nanA ortholog genes of S. mitis and S. pseudopneumoniae diverged from each other, having
shared a common ancestor. Of note, nanA genes of S. pneumoniae strains CGSP14 and NT_110_58 were distinct
from those of other pneumococcal strains. The phylogenetic analysis revealed that the GBS nonA represents a
single lineage in a cluster otherwise composed of S. iniae, which is a pathogen of fish and occasional nosocomial
infections in humans21. NonA of both S. iniae and GBS lack an LPXTG motif, which is conserved in the NanA
proteins of other streptococcus species. All streptococcal sialidases except GBS NonA possess the LamG domain
(Fig. 1A and Supplementary Fig. 2). Further analysis of the genome database indicates that five GBS strains
(GX026, SA20-06, 2-22, 138spar, and 138P) carry a nonA gene containing a nonsense mutation (Supplementary
Table 3). In addition, we measured bacterial sialidase activities using streptococcal type strains and clinical isolates (Supplementary Fig. 3). Type strains of S. oralis, S. intermedius, and S. pseudopneumoniae showed positive
sialidase activities. In contrast, the sialidase activity of S. mitis, GBS, and S. iniae strains was always below the
detection limit. Previously, Killian et al. reported that 100% of 17 S. pneumoniae and 3 S. pseudopneumoniae
strains and 69% of 54 S. mitis strains showed positive sialidase activity22. Some S. mitis strains appear to have
reduced the genome sizes and may have lost virulence-associated factors including NanA in a reductive evolutionary process23,24. Thus, it is likely that S. mitis strains exhibit a diversity of sialidase activity. Furthermore, the
result of an ancestral reconstruction technique suggests the possibility that sialidase activity was lost in the nonA
lineage rather than gained in the nanA lineage (Fig. 2). Together these results suggest that streptococcal nanA orthologs diverged into two major groups, one consisting of S. mitis, S. intermedius and S. pneumoniae, and the other
consisting of GBS and the S. iniae group. In the S. iniae/GBS group NonA appears to have lost its functional role.
To examine the relationship of pneumococcal nanA, nanB, nanC, and GBS nonA, a phylogenetic analysis
was performed using the genes. Bayesian- and maximum likelihood phylogenetic analyses of the genes
revealed similar patterns of genetic classification with high posterior probabilities or bootstrap values (Fig. 3
and Supplementary Fig. 4). The pneumococcal nanB/nanC were well separated from pneumococcal nanA
or GBS nonA. We performed an additional evolutionary analysis on nanA, nonA, nanB, nanC, bgaA, and
strH genes. BgaA and StrH, another pneumococcal exoglycosidases, remove galactose that is β1-4 linked to
N-acetylglucosamine, and N-acetylglucosamine that is β1 linked to mannose, respectively13. Selection analysis through non-synonymous/synonymous ratio calculations by Fixed Effects Likelihood (FEL) and Fast,
Unconstrained Bayesian AppRoximation (FUBAR) analyses suggested similar results. There were more codons
evolving under negative selection in the nanA genes of S. pneumoniae strains (Table 1, Supplementary Table 4
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Figure 1. Phylogenetic analysis of nanA orthologs. (A) Schematic illustration of domains in S. pneumoniae
NanA and GBS NonA. NonA lacks LamG domain and LPXTG motif conserved in NanA. (B) Bayesian
phylogenetic tree of the nanA and nonA genes. The information on bacterial strains is listed in Supplementary
Table 2. Strains with identical sequences are listed on the same branch. Percentage of posterior probabilities is
shown near the nodes. The scale bar indicates nucleotide substitutions per site. S. pneumoniae nanA and GBS
nonA genes are shaded in blue and red, respectively.
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S. agalactiae strain H002; NGBS572; 2603V/R; NEM316
S. agalactiae strain SS1; NGBS061; 09mas018883
S. agalactiae strain GBS6; GBS2-NM; GBS1-NY
S. agalactiae SA20-06
S. agalactiae strain 138spar; 138P; 2-22; strain GX026
S. agalactiae ILRI112
S. agalactiae ILRI005
S. agalactiae strain COH1
S. agalactiae A909; strain SG-M1; HN016; GD201008-001
S. pneumoniae CGSP14
S. mitis B6
S. mitis strain KCOM 1350
S. oralis Uo5
S. sp. VT 162
S. pseudopneumoniae IS7493
S. pneumoniae strain NT_110_58
S. intermedius JTH08
S. intermedius B196
S. intermedius C270
S. pneumoniae JJA
S. pneumoniae D39; R6; OXC141
S. pneumoniae 670-6B
S. pneumoniae P1031
S. pneumoniae TIGR4
S. pneumoniae 70585
S. pneumoniae G54
S. pneumoniae AP200

inactive
active
missing value

S. pneumoniae SPNA45
S. pneumoniae Hungary19A-6
S. pneumoniae ST556; Taiwan19F-14
S. pneumoniae TCH8431/19A; ATCC 700669
S. pneumoniae gamPNI0373

Figure 2. Ancestral state reconstructions based on the Bayesian phylogenetic tree. Parsimony
reconstruction using Mesquite for active or inactive sialidase phenotypes is shown as white or black lines,
respectively. Gray lines indicate missing values.

and Supplementary Figs 5–10). In contrast, fewer codons evolving under negative selection were detected in the
nonA genes of GBS as well as the nanB and nanC genes. Similar results were obtained with the bgaA and strH
genes, indicating that nanA is under strong selective pressure. On the other hand, there were no or very few
codons that appear to be evolving under positive selection in these genes. We conducted a likelihood ratio test to
investigate whether pneumococcal nanA and GBS nonA genes have the same distribution of substitution rates
across sites (Table 2). The distributions of substitution rates indicate no significant differences in between pneumococcal nanA and GBS nonA genes. However, there was a significant difference in selective regimes (dN/dS
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Clostridium perfringens strain FORC_003
Clostridium perfringens str. 13
Virgibacillus sp. SK37

S. pneumoniae nanB or nanC

0.3

Figure 3. Bayesian phylogenetic tree of nanA, nanB, nanC, and GBS nonA genes. Percentage of posterior
probabilities is shown near the nodes. Strains with identical sequences are listed on the same branch. The scale
bar indicates nucleotide substitutions per site. Blue shows pneumococcal nanA and green is nanB or nanC. GBS
nonA is shown as red.

Number of Strains

dN/dS

Codons evolving under
positive selection

Codons evolving under
negative selection

S. pneumoniae

16

0.231

0.268% (2/745)

14.362% (107/745)

S. agalactiae

16

0.315

0% (0/452)

1.991% (9/452)

nanB

S. pneumoniae

16

0.309

0% (0/454)

0.881% (4/454)

nanC

S. pneumoniae

6

0.192

0% (0/740)

2.703% (20/740)

bgaA

S. pneumoniae

14

0.194

0.313% (7/2233)

5.867% (131/2233)

strH

S. pneumoniae

17

0.595

0.152% (2/1319)

0.455% (6/1319)

Gene

Species

nanA
nonA

Table 1. Evolutionary analyses of nanA, nonA, nanB, nanC, bgaA, and strH genes. Evolutionary analysis
was performed using Baysian inference of aligned nanA, nonA, nanB, nanC, bgaA, or strH sequences from
complete genomes of S. pneumoniae or S. agalactiae, with two rate FEL in the HyPhy software package. The
dN/dS means ratio of non-synonymous changes to synonymous changes in overall analyzed genes. Individual
codons with a statistically significant signature were also calculated and are expressed as a percentage of the
total number of codons used in the analysis.
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LR

DF

P-value

The distributions

14.855

10

0.137

Selective regimes (dN/dS and proportions)

9.602

2

0.008

−0.020

1

1.000

8.120

1

0.004

Tests

Selection strength (dN/dS)
The proportions of codons under selection

Table 2. Comparing codon selection between nanA and nonA genes. Comparing codon selection was
performed using Baysian inference of aligned nanA or nonA sequences, and distribution comparison tests in
the HyPhy software package. LR; Likelihood ratio. DF; degrees of freedom.

and proportions), especially in the proportions of codons under selection. These results suggest that a functional
change of NanA would be deleterious in S. pneumoniae. In fact, pneumococcal NanA is a multifunctional protein,
that promotes bloodstream survival17 and penetration of host endothelial cell barriers system14. In contrast to
pneumococcal NanA, the GBS NonA does not appear to be under strong selective pressure, which supports our
hypothesis that NonA no longer functions in GBS.

Forced expression of NanA in GBS degrades terminal sialic acids of its capsule. To investigate
the role of NonA in bacterial pathogenesis, we constructed an isogenic GBS ΔnonA mutant strain and then
complemented the ΔnonA strain with the functional pneumococcal NanA as described in the Methods section.
The expression of the nonA gene in a GBS wild-type (WT) strain was higher than that of the well-characterized
cylE gene encoding the GBS β-hemolysin/cytolysin (Supplementary Fig. 11). Sialidase activities of GBS WT,
ΔnonA, and ΔnonA[pNanA] strains were determined using a fluorometric sialidase assay (Fig. 4A). Neither the
WT nor ΔnonA GBS strains showed sialidase activity associated the bacterial cells or culture supernatants, but
sialidase activity could be detected with heterologous expression of the pneumococcal enzyme.
We next investigated whether heterologous expression of a functional sialidase (NanA) would degrade the
terminal sialic acid moiety on the GBS capsular polysaccharide repeating unit by flow cytometry with
FITC-labeled Erythrina cristagalli agglutinin (ECA; Fig. 4B). ECA binds to terminal (unsialylated) galactose and
the ECA binding level inversely reflects the level of sialylation on the GBS capsule. GBS WT and ΔnonA mutant
strains showed similar histogram patterns and did not interact with the FITC-labeled ECA. On the other hand,
the complemented GBS ΔnonA[pNanA] strain showed substantially higher fluorescence intensity when incubated with FITC-labeled ECA as compared to the strains incubated without FITC-labeled ECA. These results
indicated that the GBS WT strain possessed no sialidase activity and the forced expression of the active sialidase
in GBS could have the effect of degrading its own terminal sialic acid, a known immune evasion virulence factor
of the pathogen with anti-complement, anti-phagocytic, and immunosuppressive properties4–8.
NonA does not contribute to GBS invasion into hBMECs.

To examine the role of GBS NonA compared to the previously established role of pneumococcal NanA in the invasion of blood-brain barrier endothelium, we performed adherence/invasion assay using human brain microvascular endothelial cells (hBMECs)
(Fig. 5). To quantify bacterial invasion, hBMECs were incubated with GBS strains for 1 hour (h) and further incubated for 1 h in medium containing antibiotics. WT GBS and the ΔnonA mutant did not differ in their adherence
or invasion phenotypes to hBMEC (Fig. 5). The association of the ΔnonA[pNanA] strain was decreased as compared to that of other strains; however, invasion of the ΔnonA[pNanA] strains into human brain microvascular
endothelial cells were significantly higher than that of GBS WT and ΔnonA strains. These results indicated that
pneumococcal NanA, but not the endogenous GBS NanA homologue, can contributes to bacterial invasion of
brain endothelial cells.

Expression of sialidase in GBS inhibits its survival.

We compared bacterial survival rate ex vivo in
human blood to compare the function of GBS NonA and active pneumococcal NanA in the GBS background
(Fig. 6). The series of GBS strains were mixed with freshly collected human blood, and the mixture incubated for
3 h. Viable cell counts were determined hourly by plating diluted samples onto THY agar. No significant change
in survival was noted comparing the isogenic ΔnonA mutant to the parent GBS WT strain. However, when NanA
was introduced in this background, survival was approximately 72–79%, 39–44%, and 23% of WT levels after 1, 2,
and 3 h, respectively. These results indicated that forced expression of NanA inhibits the survival of GBS in human
blood, likely through the degradation of its terminal sialic acid on the capsule.
Finally, to investigate the potential role of NonA vs. an active sialidase in GBS pathogenesis, we infected GBS
strains in mice intravenously, and compared bacterial CFU in blood and brains from mice 20 h after infection.
Recovered CFUs of WT and ΔnonA strains in mouse blood were almost same. However, the ΔnonA[pNanA]
expressing sialidase activity had on 14% the level of WT survival in the blood, consistent with the findings in the
human blood survival assay.

Discussion

S. pneumoniae contains three sialidases, NanA, NanB, and NanC. NanB works as a virulence factor in pneumococcal infection and NanC catalyzes intermediate metabolic compounds which acts as sialidase inhibitor25,26.
The nanC gene was reported to significantly associate with clinical isolates from invasive diseases12,27. Our evolutionary analysis indicated that ~15% of the codons in the pneumococcal nanA gene evolved under negative
selection, while few codons of nanB and nanC evolved in positive or negative selection. The results suggest
that selection pressures exist such that the key enzymatic functions of NanA may not change. In contrast to the
Scientific Reports | 6:28852 | DOI: 10.1038/srep28852
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Figure 4. NanA degrades terminal sialic acid displayed on GBS polysaccharide capsule. (A) Sialidase
activities of GBS cells and culture supernatant. After 2 h incubation at 37 °C, fluorescence of sialidase-degraded
substrate was measured with excitation and emission wavelengths of 350 and 460 nm, respectively. Data are
presented as the mean of sextuplets samples. S.E. values are represented by vertical lines. The sensitivity is
0.3 mU/mL. (B) FITC-labeled ECA binding to live GBS. Red line and blue histogram represents data for
bacterial strains incubated without or with ECA, respectively.
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Figure 5. Rate of GBS adhesion to and invasion of hBMECs. GBS strain A909 and its isogenic mutant strains
were examined for their adhesion and invasion activities. Adhesion rates were calculated by dividing CFU at
1 h after infection by CFU of original inoculum. Invasion rates were calculated by dividing CFU at 1 h after
antibiotic addition by CFU of original inoculum. Data are presented as the mean of sextuplets samples. S.E.
values are represented by vertical lines.
conservations on nanA in S. pneumoniae, the GBS NanA homologue (NonA) appears to have lost its sialidase
activity. Sialyltransferases are highly conserved in GBS strains of each serotype when compared to other glycosyltransferase genes in a same operon, and the difference in genetic diversity support a hypothesis that sialic acid is
critical for GBS survival in the human host28. Our results showed that restoration of an active sialidase function
inhibited GBS survival in human blood ex vivo and mouse blood in vivo. Therefore, sialidase activity would be
deleterious to the fitness of GBS, and GBS nonA appears to be a non-functional gene.
We recently reported a similar relationship between bacterial capsule and glycosidase in another pathogenic
streptococci, group A Streptococcus (GAS, Streptococcus pyogenes)29. Almost all serotypes of GAS express a hyaluronan exopolysaccharide capsule and contain an inactivated version of the hyaluronidase (HylA) with a single
nucleotide mutation resulting in Asp to Val substitution at amino acid position 19930. However, serotype M4
strains express an active HylA, while lacking hyaluronan capsule biosynthesis operon. The operon was predicted
to represent a more recent evolutionary acquisition in most serotypes. Although hyaluronan capsule is a major
GAS virulence factor, heterologous expression studies to generate partial encapsulation of M4 wild-type strain
and full encapsulation of an isogenic mutant ΔhylA strain did not increase virulence. In this human bacterial
pathogen, the conflicts between polysaccharide capsule and glycosidase would exert conflicting selective pressures, and resulted in mutual exclusivity. In the present work, we find a similar mutual exclusivity between sialidase activity and the GBS polysaccharide capsule.
It is widely thought that pathogenic microbes may explain some human polymorphisms31,32. Sialylated pathogens can dampen the immune response through interaction with Siglecs, and this molecular mimicry is considered to be one of the primary forces in the rapid evolution of human Siglecs4,33–35. For example, Siglec-13 and -17
may have been genetically eliminated during hominid evolution, because of interactions with pathogenic bacteria, including GBS, that cause invasive infections33. In addition, Siglec-14 and -5 expressed on neutrophils and
monocytes appear to have evolved to provide a balanced response to pathogens and infants with Siglec-14 deficiency were the most prone to GBS immune subversion36. Thus, there exists a multifaceted interaction between
pathogen and human evolution at the molecular level. The synergy of evolutionary bioinformatics and functional
analysis may help to investigate the interplay between pathogen and host within an evolutionary framework and
to identify new genetically stable therapeutic targets within pathogens and/or their human hosts.

Methods

Phylogenetic and evolutionary analysis. Phylogenetic and evolutionary analyses were performed as
previously described with minor modifications37. Homologues of nanA were searched for using tBLASTn of NCBI
BLAST38. Sequences from complete genomes with e-values <2 ×  10−85 and >40% query coverage were selected
for phylogenetic tree analysis. The sequences were aligned using MAFFT ver. 7.221 with FFT-NS-i strategy39 and
edited using by Jalview40. Regions coding sialidase domain were used for further phylogenetic analysis. Edited
sequences were aligned again using MAFFT with L-INS-i strategy. The best-fitting codon evolutionary models
for maximum likelihood and Bayesian phylogenetic trees were determined by Kakusan441. Maximum likelihood
phylogenetic trees with bootstrap values were generated by RAxML ver. 8.1.2042. To validate phylogenetic inferences, Bayesian Markov chain Monte Carlo (MCMC) analyses were performed in MrBayes ver. 3.2.543, sampling
106 generations with a confirmation that the standard deviation of split frequencies was <0.01. Phylogenetic trees
were drawn by FigTree ver. 1.4.2 (http://tree.bio.ed.ac.uk/software/figtree/) based on calculated data.
Tests for evolutionary analysis were performed on aligned common codon sequences of nanA, nonA, nanB,
nanC, bgaA, or strH genes. Complete identical sequences were excluded. Whole gene non-synonymous/synonymous (dN/dS) ratio calculations, as well as statistical tests for negative or positive selection for individual codons,
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Figure 6. NanA expression diminishes GBS survival in human blood and mouse. (A) Growth of GBS
strains in fresh human blood was determined. Bacterial cells were incubated in blood for 1, 2, and 3 h at 37 °C
in a 5% CO2 atmosphere. Next, the mixture was serially diluted and plated on THY agar. Following incubation,
the number of CFU was determined. Growth index was calculated by dividing CFU after incubation by CFU
of original inoculum. Data are presented as the mean of sextuplets samples. S.E. values are represented by
vertical lines. (B) Mice were infected with ~3.5 ×  107 CFU of GBS WT, ∆nonA, or ∆nonA[pNanA]. Blood and
brain were collected at 20 h after infection. All mice were perfused with PBS prior to brain isolation. S.E. were
represented by vertical lines. The difference between groups was analyzed using an Mann-Whitney U-test.
were performed using two-rate Fixed Effects Likelihood (FEL) and Fast Unconstrained Bayesian AppRoximation
(FUBAR) in the HyPhy software package44,45. Comparing codon selection between nanA and nonA genes was
performed using LR tests in the HyPhy44.
Ancestral states for bacterial sialidases were reconstructed in Mesquite version 3.0446 using a parsimony
model with characters treated as unordered. The reconstruction was performed on the phylogenetic tree generated by MrBayes. States of active or inactive sialidase were assigned “0” or “1” for each taxon. Unavailable data
were coded as missing.

Bacterial strains and cell lines. Streptococcal strains listed in Supplementary Table 5 were cultured in
Todd-Hewitt broth (BD Biosciences) supplemented with or without 0.2% yeast extract (BD Biosciences) (THY
or TH medium) at 37 °C. Streptococcus pseudopneumoniae ATCC BAA-960 (also called as SK1069 or CCUG
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49455)47 was kindly provided by Dr. T. Hoshino, Nagasaki University, Japan. The Escherichia coli strain TOP10
(Invitrogen) was used as a host for derivatives of plasmids pSET4s, pDCerm, and pDESTerm. All E. coli strains
were cultured in Luria-Bertani (LB) broth at 37 °C with agitation. For selection and maintenance of mutants,
antibiotics were added to the media at the following concentrations: ampicillin (Wako), 100 μg/ml for E. coli;
kanamycin (Sigma-Aldrich), 50 μg/ml for E. coli; chloramphenicol (Sigma-Aldrich), 10 μg/ml for E. coli; spectinomycin (Wako), 100 μg/ml for E. coli and 150 μg/ml for GBS; and erythromycin (Sigma-Aldrich), 400 μg/ml for
E. coli and 5 μg/ml for GBS. Human brain endothelial cell line (hBMEC) was maintained in RPMI 1640 medium
(Invitrogen) supplemented with 10% FBS, 10% NuSerum (BD), and 1% MEM nonessential amino acids, and were
incubated at 37 °C in 5% CO2.

Construction of mutant strain.

The construction of in-frame deletion mutants was conducted using a
temperature-sensitive shuttle vector, pSET4s, as reported previously48,49. During the course of construction, a
merodiploid strain was created after the first allelic replacement and then resolved to possess either mutant or
wild type alleles after the second allelic replacement. To minimize the effect of secondary mutations and epigenetic changes that may have arisen during mutagenesis, a clone possessing the wild type allele was used as a
wild-type strain. Both the wild-type and an in-frame deletion mutant strain arose from the same merodiploid
ancestor. The correct in-frame deletion of genes was confirmed by site-specific PCR using purified chromosomal DNA. To create NonA and NanA-swapped GBS strain, ΔnonA[pNanA], pNanA plasmid was introduced
respectively into GBSΔnonA strain by electroporation14. pNanA was constructed by ligating nanA gene from S.
pneumoniae strain D39 into pDESTerm plasmid50.

Sialidase activity assay. Sialidase activities of bacterial cells and supernatants were determined by
Neuraminidase assay kit (abcam). Streptococcal strains were grown to the mid-log phase (OD600 =  0.4–0.5) and
centrifuged. To prepare bacterial cell fraction, the bacterial pellet was washed by PBS and resuspended in PBS.
The supernatant was used as a supernatant fraction. The samples were incubated for 2 hours at 37 °C and fluorescence intensity was measured at Ex/Em = 350 nm/460 nm.
Real-time reverse transcription-PCR (RT-PCR) assay.

Total RNA of GBS strains grown to the exponential phase (OD600 = 0.5) was isolated with RNeasy mini kit and RNase-Free DNase Set (Qiagen). Then, cDNA
was synthesized with Transcriptor First Strand cDNA Synthesis Kit (Roche). Real-time RT-PCR analysis was
conducted using StepOnePlus Real-Time PCR system (Thermo Fisher Scientific) and KAPA SYBR Fast qPCR
Kit (KAPA Biosystems). Data for gyrA were used as internal control. Primers are listed in Supplementary Table 6.

ECA-binding assay.

ECA-binding assay was performed as previously described51. GBS strains were grown
to the mid-log phase and resuspended in PBS to adjust OD600 to 0.1. The bacteria were incubated on ice with
FITC-conjugated Erythrina cristagalli agglutinin (ECA; Vector Laboratories, CA) at 10 μg/mL for 30 min. And
then, bacterial cells were washed and resuspended in PBS. The ECA-binding activities on the surface of live bacterial cells were analyzed with a CyFlow SL flow cytometer.

hBMEC association and invasion assay.

The bacterial association to and invasion of hBMEC were
quantified with minor modifications as described previously52–54. GBS strains were grown to mid-log phase
(OD600 = 0.5) and resuspended in PBS (OD600 = 0.1). hBMECs were seeded at 2 ×  105 cells per well in RPMI1640
supplemented with 10% FBS in 24-well plates 1 d prior to bacterial infection. In each well, ~2.0 ×  106 CFU of
bacteria was added to infect with ~2.0 ×  105 hBMECs at an multiplicity of infection (MOI) of 10 in a final volume
of 500 μl, and the plate was centrifuged at 1600 rpm for 5 min to initiate their contact. To determine bacterial
adhesion, the infected cells were incubated for 1 h, washed three times with PBS, and harvested with a trypsin
and 0.025% Triton X-100 solution. The number of bacterial association was quantified by serial dilution plating.
To examine bacterial invasion, hBMECs were washed following 1 h-incubation, and 500 μL of media containing
100 μg/mL of gentamicin was added and cells were incubated for an additional 1 h. The cells were washed and
lysed, and the number of bacterial invasion was quantified. The bacterial association or invasion rate was calculated by dividing the number of bacterial association/invasion by the number of original inoculums. The invasion
rate of bacterial association was also calculated by dividing the number of bacterial invasion by the number of
bacterial association.

Blood bactericidal assay.

A blood bactericidal assay was performed as previously described52,55,56. Blood
was obtained via venopuncture from healthy donors. It was performed under written informed consent according to a protocol approved by the institutional review boards of Osaka University Graduate School of Dentistry.
The GBS cells grown to the mid-log phase were washed and resuspended in PBS, and OD600 was adjusted to 0.1.
Bacterial cells (10 μl) were combined with fresh human blood (190 μl), and then the mixture was incubated at
37 °C in 5% CO2 for 1, 2, and 3 hours. Viable cell counts were determined by plating diluted samples onto THY
agar. Growth index was calculated as the number of CFU at the specified time point/number of CFU in the initial
inoculum.

Mice infection assay.

All mouse experiments were conducted in accordance with animal protocols
approved by the Animal Care and Use Committees at Osaka University Graduate School of Dentistry (24-025-2).
CD-1 (ICR: IGS) mice (6 weeks, female; Oriental) were infected with 3.5 ×  107 CFU of GBS via the tail vein. After
20 h post-infection, blood aliquots were collected from mice just after general euthanasia. The samples of brain/
meninges were collected following perfusion with PBS. Bacterial counts in blood and brain homogenates were
determined by plating serial dilutions. Bacterial counts in brain were corrected for differences in each brain weight.
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Statistical analysis. Statistical analysis of in vitro and in vivo experiments was performed using a nonparametric analysis, Mann-Whitney U test. The tests were carried out with Graph Pad prism version 6.0 e (GraphPad
Software, Inc.). In evolutionary analysis, P < 0.1 was regarded as a significant difference as well as HyPhy default
setting.
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